- American City Business Journals•last month
Azaya Therapeutics Inc., a San Antonio-based cancer drug developer, has agreed to sell its assets to Cytori Therapeutics Inc., a specialty pharmaceutical company based in San Diego, in a deal potentially worth $170 million. Under the terms of the agreement, at closing, Cytori (CYTX) will issue $2 million of its common stock and be responsible for about $2 million of Azaya’s trade payables. Azaya Chairman John Kerr said talks with Cytori began last August.
- MarketWatch•last month
Cytori Therapeutics Inc. stock surged 7.9% to $1.78 per share in morning trade Thursday after the company said it had agreed to purchase assets from privately-held Azaya Therapeutics. Under the terms of ...
- Zacks•3 months ago
Cytori Therapeutics (CYTX) announced the publication of two year follow-up data from the scleroderma study.
CYTXW : Summary for Cytori Therapeutics Inc - Yahoo Finance
Cytori Therapeutics Inc (CYTXW)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||0.58 x 100|
|Ask||0.73 x 300|
|Day's Range||0.70 - 0.70|
|52 Week Range||0.70 - 0.70|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|